What is PYXS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.24B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PYXS?

P/E (TTM) is n/a and 52-week range is $1.03 to $5.55 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PYXS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PYXS?

The company profile lists revenue (TTM) near $18M, net income (TTM) near $-106M, EPS (TTM) near $-1.28 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Pyxis Oncology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 83M shares outstanding, ISIN US7473241013 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Pyxis Oncology Inc

$PYXS

Health Care · Biotechnology

IR Run Scenarios

$2.03

+2.01%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Employees

Website

pyxisoncology.com/

IPO

2021-10-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)